vTv Therapeutics Inc. (NASDAQ:VTVT) Given Consensus Rating of “Moderate Buy” by Brokerages

vTv Therapeutics Inc. (NASDAQ:VTVT) has received a consensus rating of “Moderate Buy” from the six analysts that are currently covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation and five have given a buy recommendation to the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $53.00.

A number of research analysts have recently weighed in on VTVT shares. TD Cowen started coverage on vTv Therapeutics in a report on Monday, January 5th. They issued a “buy” rating on the stock. Wall Street Zen upgraded vTv Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, March 14th. Weiss Ratings restated a “sell (d-)” rating on shares of vTv Therapeutics in a report on Friday, March 27th. Roth Mkm initiated coverage on vTv Therapeutics in a report on Thursday, January 22nd. They set a “buy” rating and a $58.00 price target on the stock. Finally, Evercore initiated coverage on vTv Therapeutics in a report on Thursday, March 12th. They set an “outperform” rating and a $44.00 price target on the stock.

vTv Therapeutics Stock Up 2.0%

VTVT stock opened at $38.50 on Wednesday. vTv Therapeutics has a twelve month low of $14.00 and a twelve month high of $44.00. The stock’s 50 day moving average is $37.01 and its 200-day moving average is $32.90. The firm has a market capitalization of $151.69 million, a PE ratio of -11.49 and a beta of 0.40.

vTv Therapeutics (NASDAQ:VTVT) last posted its earnings results on Tuesday, March 10th. The biotechnology company reported ($0.58) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.09) by $0.51. On average, equities research analysts anticipate that vTv Therapeutics will post -2.66 earnings per share for the current fiscal year.

Institutional Trading of vTv Therapeutics

Hedge funds have recently bought and sold shares of the business. Goldman Sachs Group Inc. bought a new stake in vTv Therapeutics during the fourth quarter worth $221,000. 683 Capital Management LLC bought a new stake in vTv Therapeutics during the fourth quarter worth $731,000. Geode Capital Management LLC lifted its holdings in vTv Therapeutics by 84.3% during the fourth quarter. Geode Capital Management LLC now owns 28,194 shares of the biotechnology company’s stock worth $1,128,000 after acquiring an additional 12,896 shares during the period. Finally, Baker BROS. Advisors LP lifted its holdings in vTv Therapeutics by 52.4% during the third quarter. Baker BROS. Advisors LP now owns 148,314 shares of the biotechnology company’s stock worth $3,463,000 after acquiring an additional 51,000 shares during the period. 17.51% of the stock is currently owned by institutional investors.

About vTv Therapeutics

vTv Therapeutics, Inc is a clinical-stage biopharmaceutical company headquartered in Westport, Connecticut, focused on discovering and developing orally administered small-molecule therapies for chronic diseases. Employing its proprietary medicinal chemistry platform, the company seeks to generate novel compounds that modulate key disease pathways while optimizing safety and pharmacokinetic properties.

The company’s lead candidate, azeliragon (TTP488), is an oral inhibitor of the receptor for advanced glycation end products (RAGE) and has completed Phase II/III clinical evaluation in early-stage Alzheimer’s disease.